UPPSALA, SWEDEN / ACCESSWIRE / September 27, 2024 / The shareholders in Senzime AB (publ)(STO:SEZI)(OTCQX:SNZZF) corp. reg. no 556565-5734 (the "Company") are hereby convened to an extraordinary general meeting on 23 October 2024 at 10.00 at Advokatfirman Lindahl's premises on Vaksalagatan 10 in Uppsala.
Notice etc.
Shareholders who wish to participate in the general meeting must:
- be registered in the share register kept by Euroclear Sweden AB on Tuesday 15 October 2024 (the record date), and
- notify his or her intention to attend the general meeting to the Company no later than Friday 18 October 2024, by mail to Advokatfirman Lindahl KB, Att: Michaela Larsson, Box 1203, 751 42 Uppsala stating "general meeting" or by e-mail to michaela.larsson@lindahl.se.
Such notification shall include the shareholder's name, personal identification number or corporate registration number, address and telephone number, number of shares, details on advisors (no more than two), if any, and, where applicable, details of representatives or proxies.
Nominee-registered shares
Shareholders whose shares are registered in the name of a nominee through a bank or other trustee must, in addition to notify his or her intention to attend the general meeting, register their shares in their own name so that the shareholder is included in the share register kept by Euroclear Sweden on 15 October 2024. Such registration may be temporary (so-called voting rights registration) and shall be requested by shareholders in such time and in accordance with the routines that the nominee determines. Voting rights registrations that have been completed by the nominee no later than 17October 2024 will be considered in the preparation of the share register.
Proxy
Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney is executed by a legal person, a certified copy of the certificate of registration or equivalent must be attached. The power of attorney may not be valid for a period exceeding five years from its issuance. The original power of attorney and certificate of registration should be submitted to the Company by mail at the address mentioned above in due time prior to the general meeting. Alternatively, the original power of attorney and certificate of registration may be brought and presented at the general meeting. The Company provides a power of attorney form at request and on the Company's website, www.senzime.com.
Number of shares and votes
As of the date of this notice, there are a total of 119,705,523 shares and votes in the Company.
Proposed agenda
1. Opening of the general meeting and election of chairman of the general meeting
2. Preparation and approval of the voting list
3. Election of one or two persons to verify the minutes
4. Approval of the agenda
5. Determination as to whether the meeting has been duly convened
6. Resolution on the approval of the board of directors' resolution on a directed share issue
7. Closing of the general meeting
Proposals to resolutions
Item 1 - Election of chairman of the general meeting
The nomination committee proposes that Mattias Prage, lawyer at Advokatfirman Lindahl KB, is elected as chairman of the general meeting or, in his absence, the person otherwise appointed by the board of directors.
Item 6 - Resolution on the approval of the board of directors' resolution on a directed share issue
On 27 September 2024 the board resolved, subject to approval by the general meeting, on a directed share issue on the terms and conditions set out below (in italics). The board proposes that the general meeting approves the board's resolution.
Subject to approval by the extraordinary general meeting, the board of directors of Senzime AB (publ), corp. reg. no. 556565-5734 (the "Company") resolves to carry out a directed issue of maximum 1,104,000 new shares, entailing an increase in the share capital of maximum SEK 138,000. The resolution shall further be governed by the following terms and conditions.
The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong only to the following persons and in accordance with the specified allocation
Name | Number of shares |
Adam Dahlberg | 700,000 |
Sorin J. Brull | 404,000 |
The reasons for deviating from the shareholders' preferential rights are that the board of directors has assessed that it would not be doable to in a time- and cost-effective manner successfully carry out rights issue on terms favorable to the Company, at the same time as the Company is in need of capital. The board of directors considers it favorable for the Company and the shareholders to take advantage of the opportunity to inject new capital from strong and reputable investors on attractive terms and in a time and cost-effective manner. The board of directors' overall assessment is that the reasons for carrying out the new share issue with deviation from the shareholders' preferential rights overweigh the principal rule that new share issues shall be carried out with preferential rights for existing shareholders, and that a new issue with deviation from the shareholders' preferential rights is therefore in the interest of the Company and its shareholders.
Subscription of shares shall be made either by payment or on a subscription list not later than October28, 2024. The board of directors shall have the right to extend the subscription period.
Payment for subscribed shares shall be made not later than October 28, 2024 (same date as the subscription). The board of directors shall have the right to extend the payment period.
The new shares are issued at a price of SEK 6.20 per share. At full subscription, the Company will thus receive SEK 6,844,800 (before issuing costs). The share premium shall be transferred to the unrestricted premium reserve.
The subscription price corresponds to the price used at re-transfer to investors pursuant to the resolution to issueshares in Appendix 3. The board of director's assessment is that the price is at market terms, since it is based on the market price at the time of the board's resolution.
The new shares entitle to dividends for the first time on the first record date for dividend that take place after the issue of new shares has been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB.
The Managing Director is entitled to make any minor changes necessary for the registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
Majority requirements
A Resolution in accordance with item 6 above requires, for its validity, support from shareholders holding not less than nine-tenths of both the shares voted and of the shares represented at the general meeting.
Processing of personal data
For information regarding the processing of your personal data, please refer to https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf
The shareholders' right to information at the general meeting
The board of directors and the CEO shall, up request by any shareholder, and where the board of directors deems that such information may be provided without significant harm to the Company, provide information in respect of any circumstances which may affect the assessment of a matter on the agenda or the Company's financial position as well as the Company's relationship to other group companies. Shareholders can submit questions in advance to the Company, to the address Verkstadsgatan 8, 753 23 Uppsala or through e-mail to Slavoljub.Grujicic@senzime.com.
Documents
Documents according to the Swedish Companies Act will be held available at the Company (Verkstadsgatan 8, Uppsala) and at the Company's website, www.senzime.com, no later than three weeks before the meeting, i.e., no later than 2October2024. The documents will also be sent, without charge, to shareholders who so request and inform the Company of their postal address.
Uppsala in September2024
Senzime AB (publ)
The board of directors
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-09-27 13:00 CEST.
Attachments
Notice of Extraordinary General Meeting in Senzime AB (publ)
SOURCE: Senzime
